

Meenakshi Devidas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2921542/publications.pdf>

Version: 2024-02-01

399
papers

29,068
citations

5430

85
h-index

6872

160
g-index

402
all docs

402
docs citations

402
times ranked

21657
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcomes in adolescent and young adult patients (16 to 30 years) compared to younger patients treated for high-risk B-lymphoblastic leukemia: report from Children's Oncology Group Study AALL0232. <i>Leukemia</i> , 2022, 36, 648-655.	3.3	14
2	Impact of the COVID-19 pandemic on pediatric oncology providers globally: A mixed-methods study. <i>Cancer</i> , 2022, 128, 1493-1502.	2.0	17
3	Association of Genetic Ancestry With the Molecular Subtypes and Prognosis of Childhood Acute Lymphoblastic Leukemia. <i>JAMA Oncology</i> , 2022, 8, 354.	3.4	35
4	Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621. <i>Journal of Clinical Oncology</i> , 2022, 40, 956-967.	0.8	42
5	Sex-based disparities in outcome in pediatric acute lymphoblastic leukemia: a Children's Oncology Group report. <i>Cancer</i> , 2022, 128, 1863-1870.	2.0	12
6	Outstanding outcomes in infants with <i>KMT2A</i> -germline acute lymphoblastic leukemia treated with chemotherapy alone: results of the Children's Oncology Group AALL0631 trial. <i>Haematologica</i> , 2022, 107, 1205-1208.	1.7	11
7	Physician Perceptions of Palliative Care for Children With Cancer in Latin America. <i>JAMA Network Open</i> , 2022, 5, e221245.	2.8	13
8	Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 2106-2118.	0.8	45
9	<i>JAK3</i> mutations and mitochondrial apoptosis resistance in T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2022, 36, 1499-1507.	3.3	6
10	Molecular Mechanisms of <i>ARID5B</i> -Mediated Genetic Susceptibility to Acute Lymphoblastic Leukemia. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1287-1295.	3.0	10
11	Persistence of Chemotherapy-Induced Peripheral Neuropathy Despite Vincristine Reduction in Childhood B-Acute Lymphoblastic Leukemia. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1167-1175.	3.0	6
12	EPID-05. A novel, clinically-relevant classification of pediatric CNS tumors for cancer registries using a clustering analysis. <i>Neuro-Oncology</i> , 2022, 24, i47-i47.	0.6	1
13	Minimal residual disease comparison between Ig/TCR PCR versus NGS assays in children with Philadelphia chromosome-positive acute lymphoblastic leukemia: A report from the COG AALL1631 study. <i>Journal of Clinical Oncology</i> , 2022, 40, 10023-10023.	0.8	1
14	Effects of age, obesity, and body surface area on asparaginase-associated toxicities during acute lymphoblastic leukemia induction therapy: A report from the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2022, 40, 7000-7000.	0.8	0
15	Genome-Wide Association Study of Susceptibility Loci for <i>TCF3-PBX1</i> Acute Lymphoblastic Leukemia in Children. <i>Journal of the National Cancer Institute</i> , 2021, 113, 933-937.	3.0	9
16	Genetics of osteonecrosis in pediatric acute lymphoblastic leukemia and general populations. <i>Blood</i> , 2021, 137, 1550-1552.	0.6	3
17	Association of <i>GATA3</i> Polymorphisms With Minimal Residual Disease and Relapse Risk in Childhood Acute Lymphoblastic Leukemia. <i>Journal of the National Cancer Institute</i> , 2021, 113, 408-417.	3.0	16
18	Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia. <i>Blood Advances</i> , 2021, 5, 504-512.	2.5	28

#	ARTICLE	IF	CITATIONS
19	Reply to A. K. Agrawal et al. Journal of Clinical Oncology, 2021, 39, 695-696.	0.8	0
20	FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALLO631. Leukemia, 2021, 35, 1279-1290.	3.3	46
21	The <i>EBF1-PDGFRB</i> T681I mutation is highly resistant to imatinib and dasatinib <i>in vitro</i> and detectable in clinical samples prior to treatment. Haematologica, 2021, 106, 2242-2245.	1.7	3
22	The Global COVID-19 Observatory and Resource Center for Childhood Cancer: A response for the pediatric oncology community by SIOP and St. Jude Global. Pediatric Blood and Cancer, 2021, 68, e28962.	0.8	8
23	Prognostic impact of minimal residual disease at the end of consolidation in NCI standard-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2021, 68, e28929.	0.8	9
24	Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia. JAMA - Journal of the American Medical Association, 2021, 325, 833.	3.8	177
25	Class II Human Leukocyte Antigen Variants Associate With Risk of Pegaspargase Hypersensitivity. Clinical Pharmacology and Therapeutics, 2021, 110, 794-802.	2.3	7
26	The cost-effectiveness of gene therapy for severe hemophilia B: a microsimulation study from the United States perspective. Blood, 2021, 138, 1677-1690.	0.6	20
27	Minimal residual disease at end of induction and consolidation remain important prognostic indicators for newly diagnosed children and young adults with very high-risk (VHR) B-lymphoblastic leukemia (B-ALL): Children's Oncology Group AALL1131.. Journal of Clinical Oncology, 2021, 39, 10004-10004.	0.8	3
28	Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children's Oncology Group AALLO932. Journal of Clinical Oncology, 2021, 39, 1437-1447.	0.8	56
29	Global effect of the COVID-19 pandemic on paediatric cancer care: a cross-sectional study. The Lancet Child and Adolescent Health, 2021, 5, 332-340.	2.7	83
30	Favorable Trisomies and <i>ETV6-RUNX1</i> Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Trial AALLO331. Journal of Clinical Oncology, 2021, 39, 1540-1552.	0.8	19
31	Targeted gene expression classifier identifies pediatric T-cell acute lymphoblastic leukemia (T-ALL) patients at high risk for end induction minimal residual disease positivity.. Journal of Clinical Oncology, 2021, 39, 10002-10002.	0.8	0
32	Prognostic Impact of CNS-2 status in T-ALL: A report from the Children's Oncology Group.. Journal of Clinical Oncology, 2021, 39, 10003-10003.	0.8	0
33	Genomic and clinical characterization of early T-cell precursor lymphoblastic lymphoma. Blood Advances, 2021, 5, 2890-2900.	2.5	3
34	Late isolated central nervous system relapse in childhood B-cell acute lymphoblastic leukemia treated with intensified systemic therapy and delayed reduced dose cranial radiation: A report from the Children's Oncology Group study AALLO2P2. Pediatric Blood and Cancer, 2021, 68, e29256.	0.8	10
35	Global Experiences of Pediatric Palliative Care Teams During the First 6 Months of the SARS-CoV-2 Pandemic. Journal of Pain and Symptom Management, 2021, 62, e91-e99.	0.6	9
36	Germline RUNX1 variation and predisposition to childhood acute lymphoblastic leukemia. Journal of Clinical Investigation, 2021, 131, .	3.9	20

#	ARTICLE	IF	CITATIONS
37	Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study. <i>Lancet Oncology</i> , The, 2021, 22, 1416-1426.	5.1	93
38	Reliability and validity of a Spanish-language measure assessing clinical capacity to sustain Paediatric Early Warning Systems (PEWS) in resource-limited hospitals. <i>BMJ Open</i> , 2021, 11, e053116.	0.8	12
39	Communication Priorities and Experiences of Caregivers of Children With Cancer in Guatemala. <i>JCO Global Oncology</i> , 2021, 7, 1529-1536.	0.8	5
40	Comparison of Current and Enhanced Risk Stratification of 21,199 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia Using Objective Risk Categorization Criteria: A Children's Oncology Group Report. <i>Blood</i> , 2021, 138, 2382-2382.	0.6	0
41	Intensification of Chemotherapy Using a Modified BFM Backbone for Children, Adolescents and Young Adults with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-L) Identifies Highly Chemorefractory Patients Who Benefit from Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2021, 138, 3487-3487.	0.6	1
42	The Impact of Genetic Ancestry on the Biology and Prognosis of Childhood Acute Lymphoblastic Leukemia. <i>Blood</i> , 2021, 138, 3476-3476.	0.6	0
43	A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in Low Risk (LR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs): A Report from Children's Oncology Group Study AALL1331. <i>Blood</i> , 2021, 138, 363-363.	0.6	8
44	Blinatumomab Associated Seizure Risk in Patients with Down Syndrome and B-Lymphoblastic Leukemia: An Interim Report from Children's Oncology Group (COG) Study AALL1731. <i>Blood</i> , 2021, 138, 2304-2304.	0.6	10
45	Non-Classical Monocyte Abundance Is an Independent Adverse Risk Factor for Relapse in Pediatric B-ALL. <i>Blood</i> , 2021, 138, 1316-1316.	0.6	0
46	A Phase 3 Randomized Trial of Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL: Safety Phase Results from Children's Oncology Group Protocol AALL1732. <i>Blood</i> , 2021, 138, 3398-3398.	0.6	3
47	Racial, Ethnic, and Socioeconomic Factors Result in Disparities in Outcome Among Children with Acute Lymphoblastic Leukemia Not Fully Attenuated By Disease Prognosticators: A Children's Oncology Group (COG) Study. <i>Blood</i> , 2021, 138, 211-211.	0.6	3
48	Mixed phenotype acute leukemia: A cohort and consensus research strategy from the Children's Oncology Group Acute Leukemia of Ambiguous Lineage Task Force. <i>Cancer</i> , 2020, 126, 593-601.	2.0	32
49	Randomized assessment of delayed intensification and two methods for parenteral methotrexate delivery in childhood B-ALL: Children's Oncology Group Studies P9904 and P9905. <i>Leukemia</i> , 2020, 34, 1006-1016.	3.3	8
50	Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0331. <i>Journal of Clinical Oncology</i> , 2020, 38, 602-612.	0.8	107
51	Interdisciplinary care of pediatric oncology patients in Central America and the Caribbean. <i>Cancer</i> , 2020, 127, 2579-2586.	2.0	4
52	Mutational and functional genetics mapping of chemotherapy resistance mechanisms in relapsed acute lymphoblastic leukemia. <i>Nature Cancer</i> , 2020, 1, 1113-1127.	5.7	32
53	Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2020, 38, 3282-3293.	0.8	136
54	Six Candidate miRNAs Associated With Early Relapse in Pediatric B-Cell Acute Lymphoblastic Leukemia. <i>Anticancer Research</i> , 2020, 40, 3147-3153.	0.5	13

#	ARTICLE	IF	CITATIONS
55	Impact of Intrathecal Triple Therapy Versus Intrathecal Methotrexate on Disease-Free Survival for High-Risk B-Lymphoblastic Leukemia: Children's Oncology Group Study AALL1131. <i>Journal of Clinical Oncology</i> , 2020, 38, 2628-2638.	0.8	41
56	Successful Outcomes of Newly Diagnosed T Lymphoblastic Lymphoma: Results From Children's Oncology Group AALL0434. <i>Journal of Clinical Oncology</i> , 2020, 38, 3062-3070.	0.8	42
57	Outcomes after late bone marrow and very early central nervous system relapse of childhood B-acute lymphoblastic leukemia: a report from the Children's Oncology Group phase III study AALL0433. <i>Haematologica</i> , 2020, 106, 46-55.	1.7	29
58	Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2020, 38, 1897-1905.	0.8	117
59	Outcomes of Patients with CRLF2-Overexpressing Acute Lymphoblastic Leukemia without Down Syndrome: A Report from the Children's Oncology Group. <i>Blood</i> , 2020, 136, 45-46.	0.6	6
60	Cranial Radiation Can be Eliminated in Most Children with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Bortezomib Potentially Improves Survival in Children with T-Cell Lymphoblastic Lymphoma (T-L): Results of Children's Oncology Group (COG) Trial AALL1231. <i>Blood</i> , 2020, 136, 11-12.	0.6	10
61	Outcomes of Patients with Down Syndrome and CRLF2-Overexpressing Acute Lymphoblastic Leukemia (ALL): A Report from the Children's Oncology Group (COG). <i>Blood</i> , 2020, 136, 44-45.	0.6	1
62	Enhanced Risk Stratification of 21,178 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia (ALL) Incorporating White Blood Count (WBC), Age, and Minimal Residual Disease (MRD) at Day 8 and 29 As Continuous Variables: A Children's Oncology Group (COG) Report. <i>Blood</i> , 2020, 136, 39-40.	0.6	2
63	Sex-Based Disparities in Outcome in Childhood Acute Lymphoblastic Leukemia (ALL): A Children's Oncology Group (COG) Report. <i>Blood</i> , 2020, 136, 38-39.	0.6	0
64	Masked hypodiploidy: Hypodiploid acute lymphoblastic leukemia (ALL) mimicking hyperdiploid ALL in children: A report from the Children's Oncology Group. <i>Cancer Genetics</i> , 2019, 238, 62-68.	0.2	32
65	Inherited genetic susceptibility to acute lymphoblastic leukemia in Down syndrome. <i>Blood</i> , 2019, 134, 1227-1237.	0.6	37
66	Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Children's Oncology Group AALL07P4. <i>Leukemia and Lymphoma</i> , 2019, 60, 1740-1748.	0.6	25
67	Impact of corticosteroid pretreatment in pediatric patients with newly diagnosed B-lymphoblastic leukemia: a report from the Children's Oncology Group. <i>Haematologica</i> , 2019, 104, e517-e520.	1.7	11
68	No evidence that G6PD deficiency affects the efficacy or safety of daunorubicin in acute lymphoblastic leukemia induction therapy. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27681.	0.8	8
69	Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children's Oncology Group. <i>British Journal of Haematology</i> , 2019, 186, 274-285.	1.2	65
70	Higher Reported Lung Dose Received During Total Body Irradiation for Allogeneic Hematopoietic Stem Cell Transplantation in Children With Acute Lymphoblastic Leukemia Is Associated With Inferior Survival: A Report from the Children's Oncology Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 513-521.	0.4	40
71	Genome-Wide Association Study of Susceptibility Loci for T-Cell Acute Lymphoblastic Leukemia in Children. <i>Journal of the National Cancer Institute</i> , 2019, 111, 1350-1357.	3.0	32
72	Hematopoietic Stem-Cell Transplantation Does Not Improve the Poor Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2019, 37, 780-789.	0.8	48

#	ARTICLE	IF	CITATIONS
73	Treatment of higher risk acute lymphoblastic leukemia in young people (CCG-1961), long-term follow-up: a report from the Children's Oncology Group. <i>Leukemia</i> , 2019, 33, 2144-2154.	3.3	11
74	Replication timing alterations in leukemia affect clinically relevant chromosome domains. <i>Blood Advances</i> , 2019, 3, 3201-3213.	2.5	15
75	Excellent long-term survival of children with Down syndrome and standard-risk ALL: a report from the Children's Oncology Group. <i>Blood Advances</i> , 2019, 3, 1647-1656.	2.5	17
76	Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG. <i>Haematologica</i> , 2019, 104, 986-992.	1.7	25
77	Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia. <i>Oncogene</i> , 2019, 38, 2241-2262.	2.6	29
78	PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2019, 51, 296-307.	9.4	384
79	Novel susceptibility variants at the ERG locus for childhood acute lymphoblastic leukemia in Hispanics. <i>Blood</i> , 2019, 133, 724-729.	0.6	44
80	Germline RUNX1 Variation and Predisposition to T-Cell Acute Lymphoblastic Leukemia in Children. <i>Blood</i> , 2019, 134, 653-653.	0.6	1
81	A Phase 2 Trial of Inotuzumab Ozogamicin (InO) in Children and Young Adults with Relapsed or Refractory (R/R) CD22+ B-Acute Lymphoblastic Leukemia (B-ALL): Results from Children's Oncology Group Protocol AALL1621. <i>Blood</i> , 2019, 134, 741-741.	0.6	36
82	FLT3 Inhibitor Correlative Laboratory Assays Impact Outcomes in KMT2A-Rearranged Infant Acute Lymphoblastic Leukemia (ALL) Patients Treated with Lestaurtinib: AALL0631, a Children's Oncology Group Study. <i>Blood</i> , 2019, 134, 1293-1293.	0.6	4
83	A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk (HR/IR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs) Demonstrates Superior Efficacy and Tolerability of Blinatumomab: A Report from Children's Oncology Group Study AALL1331. <i>Blood</i> , 2019, 134, LBA-1-LBA-1.	0.6	51
84	Prognostic factors for survival after relapsed acute lymphoblastic leukemia (ALL): A Children's Oncology Group (COG) study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 10008-10008.	0.8	31
85	Outcome in Adolescent and Young Adult (AYA) Patients Compared to Younger Patients Treated for High-Risk B-Lymphoblastic Leukemia (HR B-ALL): Report from the Children's Oncology Group Study AALLO232. <i>Blood</i> , 2019, 134, 286-286.	0.6	0
86	Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group (COG). <i>Leukemia</i> , 2018, 32, 1370-1379.	3.3	40
87	Cost comparison by treatment arm and center-level variations in cost and inpatient days on the phase III high-risk B acute lymphoblastic leukemia trial AALL0232. <i>Cancer Medicine</i> , 2018, 7, 3-12.	1.3	13
88	Hedgehog pathway mutations drive oncogenic transformation in high-risk T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2018, 32, 2126-2137.	3.3	48
89	Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , 2018, 33, 937-948.e8.	7.7	142
90	Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131. <i>Cancer</i> , 2018, 124, 1150-1159.	2.0	46

#	ARTICLE	IF	CITATIONS
91	Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: A Children's Oncology Group study. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26928.	0.8	28
92	Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL. <i>Blood</i> , 2018, 131, 1350-1359.	0.6	158
93	Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2018, 131, 995-999.	0.6	170
94	Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated <i>Erwinia</i> asparaginase, pegcrisantaspase: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26873.	0.8	48
95	Longitudinal analysis of quality-of-life outcomes in children during treatment for acute lymphoblastic leukemia: A report from the Children's Oncology Group AALL0932 trial. <i>Cancer</i> , 2018, 124, 571-579.	2.0	31
96	Severe pegaspargase hypersensitivity reaction rates (grade ≥ 3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trials. <i>Leukemia and Lymphoma</i> , 2018, 59, 1624-1633.	0.6	37
97	Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622. <i>Journal of Clinical Oncology</i> , 2018, 36, 2306-2314.	0.8	185
98	<i>TP53</i> Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children. <i>Journal of Clinical Oncology</i> , 2018, 36, 591-599.	0.8	121
99	Validation of Minimal Residual Disease as Surrogate Endpoint for Event-Free Survival in Childhood Acute Lymphoblastic Leukemia. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky069.	1.4	10
100	PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia. <i>Journal of Experimental Medicine</i> , 2018, 215, 3094-3114.	4.2	37
101	Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization. <i>Journal of Clinical Oncology</i> , 2018, 36, 2926-2934.	0.8	164
102	The genetic basis and cell of origin of mixed phenotype acute leukaemia. <i>Nature</i> , 2018, 562, 373-379.	13.7	236
103	Dysregulated transcriptional networks in KMT2A- and MLLT10-rearranged T-ALL. <i>Biomarker Research</i> , 2018, 6, 27.	2.8	9
104	Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children's Oncology Group. <i>Blood</i> , 2018, 132, 815-824.	0.6	97
105	Children's Oncology Group (COG) AALL0434: Successful Disease Control without Cranial Radiation in Newly Diagnosed T Lymphoblastic Lymphoma (T-LL). <i>Blood</i> , 2018, 132, 1000-1000.	0.6	2
106	Triple Intrathecal Therapy (Methotrexate/Hydrocortisone/Cytarabine) Does Not Improve Disease-Free Survival Versus Intrathecal Methotrexate Alone in Children with High Risk B-Lymphoblastic Leukemia: Results of Children's Oncology Group Study AALL1131. <i>Blood</i> , 2018, 132, 35-35.	0.6	7
107	COG AALL0434: A randomized trial testing nelarabine in newly diagnosed t-cell malignancy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 10500-10500.	0.8	54
108	Abstract 222: Genome-wide association study of acute lymphoblastic leukemia in children with Down syndrome. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
109	Characterization of Novel Subtypes in B Progenitor Acute Lymphoblastic Leukemia. <i>Blood</i> , 2018, 132, 565-565.	0.6	14
110	Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) for Children and Young Adults with T-Cell Acute Lymphoblastic Leukemia (T-ALL) Treated at Investigator Discretion: A Report from Children's Oncology Group (COG) AALL0434. <i>Blood</i> , 2018, 132, 659-659.	0.6	0
111	Genetics of ancestry-specific risk for relapse in acute lymphoblastic leukemia. <i>Leukemia</i> , 2017, 31, 1325-1332.	3.3	25
112	Genome-Wide Study Links <i>PNPLA3</i> Variant With Elevated Hepatic Transaminase After Acute Lymphoblastic Leukemia Therapy. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 131-140.	2.3	50
113	Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group. <i>Blood</i> , 2017, 129, 3352-3361.	0.6	236
114	The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2017, 49, 1211-1218.	9.4	693
115	Klinefelter syndrome and 47,XY syndrome in children with B cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2017, 179, 843-846.	1.2	4
116	Flow cytometric vs morphologic assessment of remission in childhood acute lymphoblastic leukemia: A report from the Children's Oncology Group (COG). <i>Leukemia</i> , 2017, , .	3.3	1
117	Neurocognitive Functioning of Children Treated for High-Risk B-Acute Lymphoblastic Leukemia Randomly Assigned to Different Methotrexate and Corticosteroid Treatment Strategies: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2017, 35, 2700-2707.	0.8	38
118	Reply to I.J. Cohen. <i>Journal of Clinical Oncology</i> , 2017, 35, 3989-3991.	0.8	2
119	Impact of Initial CSF Findings on Outcome Among Patients With National Cancer Institute Standard- and High-Risk B-Cell Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2017, 35, 2527-2534.	0.8	64
120	CA180-372: An International Collaborative Phase 2 Trial of Dasatinib and Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+) Tj ETQq0 000rgBT /Overlock 10		
121	Longitudinal analysis of quality of life outcomes in children during treatment for acute lymphoblastic leukemia: A report from the Children's Oncology Group (COG) AALL0932.. <i>Journal of Clinical Oncology</i> , 2017, 35, 10522-10522.	0.8	0
122	Efficacy of ALL Therapy for WHO2016-Defined Mixed Phenotype Acute Leukemia: A Report from the Children's Oncology Group. <i>Blood</i> , 2017, 130, 883-883.	0.6	2
123	Outcome of Children with Standard-Risk Lineage Acute Lymphoblastic Leukemia: Comparison among Different Treatment Strategies. <i>Pediatric Blood and Cancer</i> , 2016, 63, 255-261.	0.8	17
124	A Pilot Study of Intensified PEG-Asparaginase in High-risk Acute Lymphoblastic Leukemia: Children's Oncology Group Study AALL08P1. <i>Journal of Pediatric Hematology/Oncology</i> , 2016, 38, 409-417.	0.3	9
125	Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group Study AALL0232. <i>Journal of Clinical Oncology</i> , 2016, 34, 2380-2388.	0.8	301
126	Clinical and Genetic Risk Factors for Acute Pancreatitis in Patients With Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2016, 34, 2133-2140.	0.8	88

#	ARTICLE	IF	CITATIONS
127	Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia. <i>Blood</i> , 2016, 127, 558-564.	0.6	56
128	Intensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2016, 63, 54-61.	0.8	72
129	Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 11306-11311.	3.3	151
130	Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. <i>Nature Communications</i> , 2016, 7, 13331.	5.8	218
131	Deregulation of DUX4 and ERG in acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2016, 48, 1481-1489.	9.4	231
132	Prevalence and predictors of anxiety and depression after completion of chemotherapy for childhood acute lymphoblastic leukemia: A prospective longitudinal study. <i>Cancer</i> , 2016, 122, 1608-1617.	2.0	69
133	Prospective, longitudinal assessment of quality of life in children from diagnosis to 3 months off treatment for standard risk acute lymphoblastic leukemia: Results of Children's Oncology Group study <sc>AALL0331</sc>. <i>International Journal of Cancer</i> , 2016, 138, 332-339.	2.3	66
134	Anxiety, pain, and nausea during the treatment of standard-risk childhood acute lymphoblastic leukemia: A prospective, longitudinal study from the <sc>C</sc>hildren's <sc>O</sc>nology <sc>G</sc>roup. <i>Cancer</i> , 2016, 122, 1116-1125.	2.0	72
135	MLL rearrangements impact outcome in HOXA-deregulated T-lineage acute lymphoblastic leukemia: a Children's Oncology Group Study. <i>Leukemia</i> , 2016, 30, 1909-1912.	3.3	34
136	Influence of Cranial Radiotherapy on Outcome in Children With Acute Lymphoblastic Leukemia Treated With Contemporary Therapy. <i>Journal of Clinical Oncology</i> , 2016, 34, 919-926.	0.8	111
137	Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children's Oncology Group Randomized Trial Pediatric Oncology Group 9404. <i>Journal of Clinical Oncology</i> , 2016, 34, 854-862.	0.8	154
138	Comprehensive Functional Characterization of Germline ETV6 Variants Associated with Inherited Predisposition to Acute Lymphoblastic Leukemia in Children. <i>Blood</i> , 2016, 128, 1085-1085.	0.6	1
139	Residual Disease Monitoring By High Throughput Sequencing Provides Risk Stratification in Childhood B-ALL and Identifies a Novel Subset of Patients Having Poor Outcome. <i>Blood</i> , 2016, 128, 1086-1086.	0.6	2
140	Anti-Pegaspargase, Anti-Calaspargase Pegol , and Anti-Polyethelene Glycol Antibody Incidence in High Risk Acute Lymphoblastic Leukemia Patients Receiving Pegaspargase or Calaspargase Pegol and Associated Anaphylactic or Hypersensitivity Reaction Rates: Results from Children's Oncology Group (COG) Study AALL07P4. <i>Blood</i> , 2016, 128, 3965-3965.	0.6	5
141	Outcomes of Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia Based on Blast Genotype at Diagnosis: A Report from the Children's Oncology Group. <i>Blood</i> , 2016, 128, 451-451.	0.6	4
142	Genomic Landscape of Pediatric Mixed Phenotype Acute Leukemia. <i>Blood</i> , 2016, 128, 454-454.	0.6	4
143	PRC2 Mutations Induce Resistance to Conventional Chemotherapy By Inhibiting Mitochondrial Apoptosis in T-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 604-604.	0.6	1
144	Minimal Residual Disease Assessment of Remission after Induction Therapy Is Superior to Morphologic Assessment for Risk Stratification in Childhood Acute Lymphoblastic Leukemia: A Report from the Children's Oncology Group (COG). <i>Blood</i> , 2016, 128, 758-758.	0.6	1

#	ARTICLE	IF	CITATIONS
145	Plasma asparaginase activity and asparagine depletion in patients with acute lymphoblastic leukemia (ALL) treated with pegaspargase (SS-PEG <i>E. coli</i> L-asparaginase): Results from Children's Oncology Group (COG) study AALL07P4.. <i>Journal of Clinical Oncology</i> , 2016, 34, 10508-10508.	0.8	3
146	Mutational Landscape, Clonal Evolution Patterns and Role of RAS Mutations in Relapsed Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 4068-4068.	0.6	0
147	Integrated Genomic Analysis of Down Syndrome Acute Lymphoblastic Leukemia Reveals Recurrent Cancer Gene Alterations and Evidence of Frequent Subclonal Driver Events. <i>Blood</i> , 2016, 128, 4083-4083.	0.6	0
148	New Insights into Deregulated Gene Expression Pathways in MLL- and AF10-Rearranged T-Lineage Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 2906-2906.	0.6	0
149	Evaluation of Minimal Residual Disease As a Surrogate Endpoint for Event Free Survival in Childhood B-Lineage Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 759-759.	0.6	0
150	Whole Exome Sequencing of Pediatric Acute Lymphoblastic Leukemia Patients Identify Mutations in 11 Pathways: A Report from the Children's Oncology Group. <i>Blood</i> , 2016, 128, 455-455.	0.6	1
151	Decreased induction morbidity and mortality following modification to induction therapy in infants with acute lymphoblastic leukemia enrolled on AALL0631: A report from the children's oncology group. <i>Pediatric Blood and Cancer</i> , 2015, 62, 414-418.	0.8	31
152	A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. <i>Blood</i> , 2015, 125, 680-686.	0.6	110
153	Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232. <i>Blood</i> , 2015, 126, 964-971.	0.6	287
154	Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia. <i>Blood</i> , 2015, 126, 1770-1776.	0.6	102
155	Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1171-1175.	0.8	89
156	Survivors of standard risk acute lymphoblastic leukemia do not have increased risk for overweight and obesity compared to non-cancer peers: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1035-1041.	0.8	32
157	Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1176-1183.	0.8	76
158	Genome-wide analysis links NFATC2 with asparaginase hypersensitivity. <i>Blood</i> , 2015, 126, 69-75.	0.6	64
159	Increased post-induction intensification improves outcome in children and adolescents with a markedly elevated white blood cell count ($\geq 10 \times 10^9/l$) with T cell acute lymphoblastic leukaemia but not B cell disease: a report from the Children's Oncology Group. <i>British Journal of Haematology</i> , 2015, 168, 533-546.	1.2	23
160	Associations between genetic variants in folate and drug metabolizing pathways and relapse risk in pediatric acute lymphoid leukemia on CCG-1952. <i>Leukemia Research Reports</i> , 2015, 4, 47-50.	0.2	2
161	Inherited coding variants at the CDKN2A locus influence susceptibility to acute lymphoblastic leukaemia in children. <i>Nature Communications</i> , 2015, 6, 7553.	5.8	72
162	Association of an Inherited Genetic Variant With Vincristine-Related Peripheral Neuropathy in Children With Acute Lymphoblastic Leukemia. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 815.	3.8	234

#	ARTICLE	IF	CITATIONS
163	Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia. <i>Nature Communications</i> , 2015, 6, 6604.	5.8	281
164	Intensified chemotherapy without SCT in infant ALL: Results from COG P9407 (Cohort 3). <i>Pediatric Blood and Cancer</i> , 2015, 62, 419-426.	0.8	61
165	Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: a systematic genetic study. <i>Lancet Oncology</i> , The, 2015, 16, 1659-1666.	5.1	161
166	Comparative evaluation of local control strategies in localized Ewing sarcoma of bone: A report from the Children's Oncology Group. <i>Cancer</i> , 2015, 121, 467-475.	2.0	124
167	Abstract 4729: Frequency of actionable gene fusions in patients with Philadelphia chromosome-like (Ph-like) B-acute lymphoblastic leukemia (ALL): A retrospective study from the Children's Oncology Group (COG)., 2015, , .		1
168	Incidence of Allergic Reactions to Pegaspargase (PEG) Administered Intramuscularly Versus Intravenously (IM vs. IV) in Children and Young Adults with High Risk B-Lymphoblastic Leukemia (HR Tj ETQq0 0 0 ggBT /Overlock 10 Tf 1303-1303.	0.6	6
169	Treatment-Related Mortality (TRM) in Children with Down Syndrome (DS) and B-Lymphoblastic Leukemia (B-ALL): An Interim Report from the Children's Oncology Group Trials AALL0932 and AALL1131. <i>Blood</i> , 2015, 126, 2502-2502.	0.6	8
170	The Genomic Landscape of Childhood T-Lineage Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 691-691.	0.6	4
171	Expression of an Oncogenic ERG isoform Characterizes a Distinct Subtype of B-Progenitor Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 693-693.	0.6	1
172	Mixed Lineage Leukemia Rearrangements (MLL-R) Are Determinants of High Risk Disease in Homeobox A (HOXA)-deregulated T-Lineage Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. <i>Blood</i> , 2015, 126, 694-694.	0.6	2
173	Capizzi-Style Methotrexate with Pegaspargase (C-MTX) Is Superior to High-Dose Methotrexate (HDMTX) in T-Lineage Acute Lymphoblastic Leukemia (T-ALL): Results from Children's Oncology Group (COG) AALL0434. <i>Blood</i> , 2015, 126, 794-794.	0.6	12
174	Genetic and Response-Based Risk Classification Identifies a Subgroup of NCI High Risk Childhood B-Lymphoblastic Leukemia (HR B-ALL) with Outstanding Outcomes: A Report from the Children's Oncology Group (COG). <i>Blood</i> , 2015, 126, 807-807.	0.6	5
175	Outcomes of dasatinib plus intensive chemotherapy or stem cell transplant (SCT) for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) on Children's Oncology Group AALL0622.. <i>Journal of Clinical Oncology</i> , 2015, 33, 10006-10006.	0.8	9
176	Germline Genetic Variation in ETV6 and Predisposition to Childhood Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 695-695.	0.6	2
177	TPMT and MTHFR genotype is not associated with altered risk of thioguanine-related sinusoidal obstruction syndrome in pediatric acute lymphoblastic leukemia: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2014, 61, 2086-2088.	0.8	11
178	A prospective study of anxiety, depression, and behavioral changes in the first year after a diagnosis of childhood acute lymphoblastic leukemia. <i>Cancer</i> , 2014, 120, 1417-1425.	2.0	107
179	Family life events in the first year of acute lymphoblastic leukemia therapy: A children's oncology group report. <i>Pediatric Blood and Cancer</i> , 2014, 61, 2277-2284.	0.8	37
180	Dose Intensification of Methotrexate and Cytarabine During Intensified Continuation Chemotherapy for High-risk B-Precursor Acute Lymphoblastic Leukemia. <i>Journal of Pediatric Hematology/Oncology</i> , 2014, 36, 353-361.	0.3	8

#	ARTICLE	IF	CITATIONS
181	Philadelphia chromosome-negative very high-risk acute lymphoblastic leukemia in children and adolescents: results from Children's Oncology Group Study AALL0031. <i>Leukemia</i> , 2014, 28, 964-967.	3.3	29
182	Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group Study AALL0031. <i>Leukemia</i> , 2014, 28, 1467-1471.	3.3	384
183	An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome. <i>Leukemia</i> , 2014, 28, 1015-1021.	3.3	175
184	Cytogenetics and outcome of infants with acute lymphoblastic leukemia and absence of MLL rearrangements. <i>Leukemia</i> , 2014, 28, 428-430.	3.3	22
185	Pharmacokinetic and Pharmacodynamic Properties of Calaspargase Pegol <i>Escherichia coli</i> L-Asparaginase in the Treatment of Patients With Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Study AALL07P4. <i>Journal of Clinical Oncology</i> , 2014, 32, 3874-3882.	0.8	91
186	Pharmacokinetics and pharmacogenomics of daunorubicin in children: a report from the Children's Oncology Group. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 831-838.	1.1	21
187	Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2014, 371, 1005-1015.	13.9	1,161
188	HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies. <i>Blood</i> , 2014, 124, 1266-1276.	0.6	84
189	T-Lymphoblastic Leukemia (T-ALL) Shows Excellent Outcome, Lack of Significance of the Early Thymic Precursor (ETP) Immunophenotype, and Validation of the Prognostic Value of End-Induction Minimal Residual Disease (MRD) in Children's Oncology Group (COG) Study AALL0434. <i>Blood</i> , 2014, 124, 1-1.	0.6	113
190	Effect of High-Dose Methotrexate (HD-MTX) Vs Capizzi Methotrexate/Pegaspargase (C-MTX/ASNase) on Osteonecrosis (ON) Incidence in Children and Young Adults with T-Acute Lymphoblastic Leukemia (T-ALL): Results of Children's Oncology Group (COG) Study AALL0434. <i>Blood</i> , 2014, 124, 3649-3649.	0.6	5
191	Glutamate Receptor Polymorphisms Contribute to Glucocorticoid-Associated Osteonecrosis. <i>Blood</i> , 2014, 124, 367-367.	0.6	1
192	Outcomes after Intermediate-Risk Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL) and the Role of Allogeneic Stem Cell Transplantation (SCT): A Report from Children's Oncology Group (COG) AALL0433. <i>Blood</i> , 2014, 124, 684-684.	0.6	4
193	Outstanding Outcome for Children with Standard Risk-Low (SR-Low) Acute Lymphoblastic Leukemia (ALL) and No Benefit to Intensified Peg-Asparaginase (PEG-ASNase) Therapy: Results of Children's Oncology Group (COG) Study AALL0331. <i>Blood</i> , 2014, 124, 793-793.	0.6	15
194	The significance of minimal residual disease (MRD) in relapsed childhood B-lymphoblastic leukemia (B-ALL): A report from Children's Oncology Group (COG) protocol AALL0433. <i>Journal of Clinical Oncology</i> , 2014, 32, 10014-10014.	0.8	3
195	The impact of initial cerebrospinal fluid (CSF) findings on outcome among patients with NCI standard (SR) and high-risk (HR) B-lymphoblastic leukemia (ALL): A report from the Children's Oncology Group (COG) Studies AALL0331 and AALL0232. <i>Journal of Clinical Oncology</i> , 2014, 32, 10016-10016.	0.8	1
196	Prospective assessment of chemotherapy-induced peripheral neuropathy (CIPN) in children with standard-risk acute lymphoblastic leukemia (SR ALL): Results of Children's Oncology Group (COG) AALL0932. <i>Journal of Clinical Oncology</i> , 2014, 32, 7056-7056.	0.8	1
197	Abstract 3083: The genetic landscape of Ph-like acute lymphoblastic leukemia. , 2014, , .		0
198	Abstract 998: Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukemia (B-ALL): A report from the children's oncology group (COG) - Target - St. Jude Pediatric Cancer Genome Project. , 2014, , .		0

#	ARTICLE	IF	CITATIONS
199	Genetic Variation in NFATC2 Is Associated with a Higher Risk of Asparaginase Allergy. <i>Blood</i> , 2014, 124, 63-63.	0.6	6
200	Resource Utilization and Cost Analysis By Treatment Arm on the Children's Oncology Group AALL0232 Phase 3 High-Risk B-Precursor Acute Lymphoblastic Leukemia Trial: A Report from the Children's Oncology Group. <i>Blood</i> , 2014, 124, 210-210.	0.6	0
201	Second Malignant Neoplasms After Treatment of Childhood Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2013, 31, 2469-2476.	0.8	120
202	<i>Erwinia</i> asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group. <i>Blood</i> , 2013, 122, 507-514.	0.6	63
203	Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project. <i>Blood</i> , 2013, 121, 485-488.	0.6	156
204	Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2013, 60, 957-963.	0.8	149
205	Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. <i>Nature Genetics</i> , 2013, 45, 1494-1498.	9.4	264
206	Considerations in the design of clinical trials for pediatric acute lymphoblastic leukemia. <i>Clinical Investigation</i> , 2013, 3, 849-858.	0.0	7
207	Treatment of Relapsed Precursor-B Acute Lymphoblastic Leukemia With Intensive Chemotherapy. <i>Journal of Pediatric Hematology/Oncology</i> , 2013, 35, 509-513.	0.3	7
208	Chemotherapy for Initial Induction Failures in Childhood Acute Lymphoblastic Leukemia. <i>Journal of Pediatric Hematology/Oncology</i> , 2013, 35, 32-35.	0.3	2
209	Novel Susceptibility Variants at 10p12.31-12.2 for Childhood Acute Lymphoblastic Leukemia in Ethnically Diverse Populations. <i>Journal of the National Cancer Institute</i> , 2013, 105, 733-742.	3.0	208
210	Intrachromosomal Amplification of Chromosome 21 Is Associated With Inferior Outcomes in Children With Acute Lymphoblastic Leukemia Treated in Contemporary Standard-Risk Children's Oncology Group Studies: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2013, 31, 3397-3402.	0.8	125
211	The genomic landscape of hypodiploid acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2013, 45, 242-252.	9.4	588
212	Potent obatoxax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemia. <i>Blood</i> , 2013, 121, 2689-2703.	0.6	53
213	Genome-wide study of methotrexate clearance replicates SLCO1B1. <i>Blood</i> , 2013, 121, 898-904.	0.6	174
214	Genomic Characterization and Experimental Modeling Of BCR-ABL1-Like Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013, 122, 232-232.	0.6	8
215	Genome-Wide DNA Methylation Analysis Reveals Biological and Clinical Insights In Relapsed Childhood Acute Lymphoblastic Leukemia: A Report From The COG ALL Target Project. <i>Blood</i> , 2013, 122, 3736-3736.	0.6	1
216	Frontline-Treatment Of Acute Lymphoblastic Leukemia (ALL) In Older Adolescents and Young Adults (AYA) Using a Pediatric Regimen Is Feasible: Toxicity Results of the Prospective US Intergroup Trial C10403 (Alliance). <i>Blood</i> , 2013, 122, 3903-3903.	0.6	35

#	ARTICLE	IF	CITATIONS
217	HLA-DRB1*07:01 Is Associated With Asparaginase Allergies In Children With Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013, 122, 60-60.	0.6	1
218	Genome-Wide Association Analyses Identify Susceptibility Loci For Vincristine-Induced Peripheral Neuropathy In Children With Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013, 122, 618-618.	0.6	6
219	Comparison Of Mutational Profiles Of Diagnosis and Relapsed Pediatric B-Acute Lymphoblastic Leukemia: A Report From The COG ALL Target Project. <i>Blood</i> , 2013, 122, 824-824.	0.6	4
220	Integrated Genomic and Mutational Profiling Of Adolescent and Young Adult ALL Identifies a High Frequency Of BCR-ABL1-Like ALL with Very Poor Outcome. <i>Blood</i> , 2013, 122, 825-825.	0.6	8
221	Excellent Event Free (EFS) and Overall Survival (OS) For Children With Standard Risk Acute Lymphoblastic Leukemia (SR ALL) Despite The Absence Of a Significant Impact On Outcome With The Addition Of An Intensified Consolidation: Results Of Children's Oncology Group (COG) AALL0331. <i>Blood</i> , 2013, 122, 837-837.	0.6	13
222	Assessment of end induction minimal residual disease (MRD) in childhood B precursor acute lymphoblastic leukemia (ALL) to eliminate the need for day 14 marrow examination: A Children's Oncology Group study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 10001-10001.	0.8	4
223	Effect of dexamethasone (DEX) dose modification on osteonecrosis (ON) risk associated with intensified therapies for standard risk acute lymphoblastic leukemia (SR-ALL): A report from the Children's Oncology Group (COG) study AALL0331.. <i>Journal of Clinical Oncology</i> , 2013, 31, 10002-10002.	0.8	1
224	Bortezomib reinduction therapy to improve response rates in pediatric ALL in first relapse: A Children's Oncology Group (COG) study (AALL07P1).. <i>Journal of Clinical Oncology</i> , 2013, 31, 10003-10003.	0.8	11
225	Risk Factors For Acute Pancreatitis In Patients With Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013, 122, 3868-3868.	0.6	0
226	Leukemic Blasts With The PNH Phenotype: Correlation With Cytogenetics In ALL. <i>Blood</i> , 2013, 122, 2628-2628.	0.6	0
227	Outcomes after Induction Failure in Childhood Acute Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2012, 366, 1371-1381.	13.9	252
228	Reply to A. Bleyer et al. <i>Journal of Clinical Oncology</i> , 2012, 30, 4038-4039.	0.8	3
229	<i>ARID5B</i> Genetic Polymorphisms Contribute to Racial Disparities in the Incidence and Treatment Outcome of Childhood Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2012, 30, 751-757.	0.8	165
230	Pilot Study of Nelarabine in Combination With Intensive Chemotherapy in High-Risk T-Cell Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2012, 30, 2753-2759.	0.8	82
231	Plasma Methotrexate, Red Blood Cell Methotrexate, and Red Blood Cell Folate Values and Outcome in Children With Precursor B-acute Lymphoblastic Leukemia. <i>Journal of Pediatric Hematology/Oncology</i> , 2012, 34, e1-e7.	0.3	16
232	Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children's Oncology Group study. <i>Blood</i> , 2012, 119, 1872-1881.	0.6	110
233	Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group Study. <i>Blood</i> , 2012, 119, 3512-3522.	0.6	210
234	Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. <i>Blood</i> , 2012, 120, 4197-4204.	0.6	103

#	ARTICLE	IF	CITATIONS
235	Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , 2012, 22, 153-166.	7.7	621
236	Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2012, 30, 1663-1669.	0.8	944
237	Phase II Trial of Trastuzumab in Combination With Cytotoxic Chemotherapy for Treatment of Metastatic Osteosarcoma With Human Epidermal Growth Factor Receptor 2 Overexpression: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2012, 30, 2545-2551.	0.8	204
238	Effect of alternate-week versus continuous dexamethasone scheduling on the risk of osteonecrosis in paediatric patients with acute lymphoblastic leukaemia: results from the CCG-1961 randomised cohort trial. <i>Lancet Oncology</i> , The, 2012, 13, 906-915.	5.1	143
239	Pediatric acute lymphoblastic leukemia with a t(8;14)(q11.2;q32): B-cell disease with a high proportion of Down syndrome: a Children's Oncology Group study. <i>Cancer Genetics</i> , 2012, 205, 453-458.	0.2	13
240	The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. <i>Nature</i> , 2012, 481, 157-163.	13.7	1,430
241	Abnormal developmental control of replication-timing domains in pediatric acute lymphoblastic leukemia. <i>Genome Research</i> , 2012, 22, 1833-1844.	2.4	89
242	Germline genetic variation and treatment response on CCG-1891. <i>Pediatric Blood and Cancer</i> , 2012, 58, 695-700.	0.8	24
243	Modifications to induction therapy decrease risk of early death in infants with acute lymphoblastic leukemia treated on Children's Oncology Group P9407. <i>Pediatric Blood and Cancer</i> , 2012, 59, 834-839.	0.8	29
244	Continuous Dose Dasatinib Is Safe and Feasible in Combination with Intensive Chemotherapy in Pediatric Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Children's Oncology Group (COG) Trial AALL0622. <i>Blood</i> , 2012, 120, 137-137.	0.6	7
245	A Genome-Wide Analysis of Variants Influencing Methotrexate Clearance Replicates SLCO1B1.. <i>Blood</i> , 2012, 120, 2466-2466.	0.6	5
246	Identification of CRLF2 Genomic Lesions in Patients with Pediatric B-Precursor Acute Lymphoblastic Leukemia (BCP ALL) by Flow Cytometry or Quantitative RT-PCR: A Children's Oncology Group (COG) Stud.. <i>Blood</i> , 2012, 120, 2529-2529.	0.6	10
247	Effects of Dexamethasone (DEX) Vs Prednisone (PDN) and High-Dose Methotrexate (HD-MTX) Vs Capizzi Methotrexate/Asparaginase (C-MTX/ASNase) On Osteonecrosis (ON) Incidence in Children and Young Adults with High Risk Acute Lymphoblastic Leukemia (HR-ALL): A Report From the Children's Oncology Group (COG) Study AALL0232. <i>Blood</i> , 2012, 120, 665-665.	0.6	3
248	Cardioprotection and safety of dexrazoxane (DRZ) in children treated for newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL) or advanced stage lymphoblastic leukemia (T-LL).. <i>Journal of Clinical Oncology</i> , 2012, 30, 9504-9504.	0.8	12
249	Evaluation of local control strategies in patients with localized Ewing sarcoma of bone: A report from the Children's Oncology Group.. <i>Journal of Clinical Oncology</i> , 2012, 30, 9537-9537.	0.8	1
250	Safety and biological activity of the FLT3 inhibitor lestaurtinib in infant MLL-rearranged (MLL-r) ALL: Children's Oncology Group protocol AALL0631.. <i>Journal of Clinical Oncology</i> , 2012, 30, 9548-9548.	0.8	2
251	Outcome in adolescent and young adult (AYA) patients compared with younger patients treated for high-risk B-precursor acute lymphoblastic leukemia (HR-ALL): A report from the Children's Oncology Group study AALL0232.. <i>Journal of Clinical Oncology</i> , 2012, 30, CRA9508-CRA9508.	0.8	6
252	Abstract 4870: Integrated genomic analysis of hypodiploid acute lymphoblastic leukemia. , 2012, , .		1

#	ARTICLE	IF	CITATIONS
253	Outcome in adolescent and young adult (AYA) patients compared with younger patients treated for high-risk B-precursor acute lymphoblastic leukemia (HR-ALL): A report from the Children's Oncology Group study AALL0232.. Journal of Clinical Oncology, 2012, 30, CRA9508-CRA9508.	0.8	0
254	Pharmacokinetic (PK) and pharmacodynamics (PD) properties of SC-PEG <i>e. coli</i> L-asparaginase (EZN-2285) in the treatment of patients with acute lymphoblastic leukemia (ALL): Results from Children's Oncology Group (COG) study AALL07P4.. Journal of Clinical Oncology, 2012, 30, 9543-9543.	0.8	1
255	Trends in body mass index (BMI) during and after treatment for standard risk (SR) acute lymphoblastic leukemia (ALL): A report from the Children's Oncology Group (COG).. Journal of Clinical Oncology, 2012, 30, 9546-9546.	0.8	0
256	Comparison of High-Throughput Sequencing and Flow Cytometry for Measuring Minimal Residual Disease in Pediatric Acute Lymphoblastic Leukemia: A Children's Oncology Group Cohort. Blood, 2012, 120, 1440-1440.	0.6	0
257	Genome-Wide Association Study Identifies a Novel Susceptibility Locus At 10p12.31-12.2 for Childhood Acute Lymphoblastic Leukemia in Ethnically Diverse Populations. Blood, 2012, 120, 877-877.	0.6	2
258	IKZF1 and 22q11.22 Deletions and PDGFRA Gains Are Associated with Poor Outcome in Down Syndrome Acute Lymphoblastic Leukemia. Blood, 2012, 120, 289-289.	0.6	4
259	Expression Profiling for MEIS1 and HOXA9/10 Identifies an Increased Incidence of MLL Rearrangements in T-ALL: A Children's Oncology Group Study.. Blood, 2012, 120, 2505-2505.	0.6	0
260	Genomic profiling in Down syndrome acute lymphoblastic leukemia identifies histone gene deletions associated with altered methylation profiles. Leukemia, 2011, 25, 1555-1563.	3.3	43
261	Non-metastatic unresected paediatric non-rhabdomyosarcoma soft tissue sarcomas: Results of a pooled analysis from United States and European groups. European Journal of Cancer, 2011, 47, 724-731.	1.3	123
262	Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children's Oncology Group (POG 9404). Blood, 2011, 118, 874-883.	0.6	150
263	Postrelapse survival in childhood acute lymphoblastic leukemia is independent of initial treatment intensity: a report from the Children's Oncology Group. Blood, 2011, 117, 3010-3015.	0.6	67
264	Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood, 2011, 118, 243-251.	0.6	126
265	Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood, 2011, 118, 3080-3087.	0.6	255
266	Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nature Genetics, 2011, 43, 237-241.	9.4	239
267	Frequency and prognostic implications of JAK 1-3 aberrations in Down syndrome acute lymphoblastic and myeloid leukemia. Leukemia, 2011, 25, 1365-1368.	3.3	20
268	Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: Results of Children's Oncology Group trial P9906. Pediatric Blood and Cancer, 2011, 57, 569-577.	0.8	55
269	Analysis of the Role of Hematopoietic Stem-Cell Transplantation in Infants With Acute Lymphoblastic Leukemia in First Remission and <i>MLL</i> Gene Rearrangements: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2011, 29, 214-222.	0.8	85
270	Improved Post-Induction Chemotherapy Does Not Abrogate Prognostic Significance of Minimal Residual Disease (MRD) for Children and Young Adults with High Risk Acute Lymphoblastic Leukemia (ALL). A Report From Children's Oncology Group (COG) Study AALL0232. Blood, 2011, 118, 1440-1440.	0.6	3

#	ARTICLE	IF	CITATIONS
271	TREATMENT Toxicity in Adolescents and Young ADULT (AYA) PATIENTS COMPARED with Younger PATIENTS TREATED for HIGH RISK B-Precursor ACUTE LYMPHOBLASTIC LEUKEMIA (HR-ALL): A REPORT From the CHILDREN'S Oncology GROUP STUDY AALL0232. <i>Blood</i> , 2011, 118, 1510-1510.	0.6	12
272	Reinduction Chemoimmunotherapy with Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL) in Children, Adolescents and Young Adults: Results From Children's Oncology Group (COG) Study ADVL04P2. <i>Blood</i> , 2011, 118, 573-573.	0.6	21
273	A BCR-ABL1-Like Gene Expression Profile Confers a Poor Prognosis In Patients with High-Risk Acute Lymphoblastic Leukemia (HR-ALL): A Report From Children's Oncology Group (COG) AALL0232. <i>Blood</i> , 2011, 118, 743-743.	0.6	3
274	Strategies for New Agent Development and Clinical Trial Considerations. <i>Pediatric Oncology</i> , 2011, , 215-241.	0.5	1
275	Abstract 4755: Genome wide analysis of hypodiploid acute lymphoblastic leukemia identifies a high frequency of mutations targeting the IKAROS gene family and Ras signaling. , 2011, , .		0
276	iAMP21 Is Associated with Inferior Outcomes in Children with Acute Lymphoblastic Leukemia (ALL) on Contemporary Children's Oncology Group (COG) Studies. <i>Blood</i> , 2011, 118, 739-739.	0.6	2
277	Novel Chromosomal Rearrangements and Sequence Mutations in High-Risk Ph-Like Acute Lymphoblastic Leukemia. <i>Blood</i> , 2011, 118, 67-67.	0.6	0
278	Discovery of Novel Recurrent Mutations in Childhood Early T-Cell Precursor Acute Lymphoblastic Leukemia by Whole Genome Sequencing - a Report From the St Jude Children's Research Hospital - Washington University Pediatric Cancer Genome Project. <i>Blood</i> , 2011, 118, 68-68.	0.6	0
279	Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology Group. <i>Blood</i> , 2010, 116, 1045-1050.	0.6	77
280	Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. <i>Blood</i> , 2010, 116, 4874-4884.	0.6	370
281	The Use of Central Laboratories and Remote Electronic Data Capture to Risk-Adjust Therapy for Pediatric Acute Lymphoblastic Leukemia and Neuroblastoma. <i>Seminars in Oncology</i> , 2010, 37, 53-59.	0.8	27
282	Folypolyglutamate Synthetase Gene Transcription is Regulated by a Multiprotein Complex that Binds the TEL-AML1 Fusion in Acute Lymphoblastic Leukemia. <i>Leukemia Research</i> , 2010, 34, 1601-1609.	0.4	12
283	Systematic review of the addition of vincristine plus steroid pulses in maintenance treatment for childhood acute lymphoblastic leukaemia – an individual patient data meta-analysis involving 5659 children. <i>British Journal of Haematology</i> , 2010, 149, 722-733.	1.2	40
284	Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984–2001: a report from the children's oncology group. <i>Leukemia</i> , 2010, 24, 355-370.	3.3	214
285	Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983–2002: A Children's Oncology Group Report. <i>Leukemia</i> , 2010, 24, 285-297.	3.3	245
286	Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia. <i>Blood</i> , 2010, 115, 1394-1405.	0.6	192
287	Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. <i>Blood</i> , 2010, 115, 5312-5321.	0.6	503
288	T-Cell Receptor Gene Deletions Are Associated with High Risk Features and Worse Outcome In Childhood Precursor B-Cell Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2010, 116, 275-275.	0.6	1

#	ARTICLE	IF	CITATIONS
289	Lack of Somatic Sequence Mutations In Protein Tyrosine Kinase Genes Other Than the JAK Kinase Family In High Risk B-Precursor Childhood Acute Lymphoblastic Leukemia (ALL): A Report From the Children's Oncology Group (COG) High-Risk (HR) ALL TARGET Project. <i>Blood</i> , 2010, 116, 2752-2752.	0.6	7
290	Infant Acute Lymphoblastic Leukemias Are Pan-Sensitive to Obatoclox Across molecular/Cytogenetic Subtypes, Especially MLL-ENL, and gene Expression Profiles Determine Obatoclox IC50: A Report on the Children's Oncology Group (COG) P9407 Trial. <i>Blood</i> , 2010, 116, 2757-2757.	0.6	1
291	Genome-Wide Analysis of Genetic Alterations In Hypodiploid Acute Lymphoblastic Leukemia Identifies a High Frequency of Mutations Targeting the IKAROS Gene Family and Ras Signaling. <i>Blood</i> , 2010, 116, 411-411.	0.6	3
292	Children with Down Syndrome (DS) and NCI Standard Risk (SR) Acute Lymphoblastic Leukemia (ALL) Have a Superior Five-Year Event-Free Survival (EFS) When Treated with Escalating Intravenous Methotrexate on the Children's Cancer Group (CCG) Study 1991. <i>Blood</i> , 2010, 116, 497-497.	0.6	1
293	Early Response Characteristics and Blast Cytogenetic Features In 5,377 Children with Standard Risk Acute Lymphoblastic Leukemia (SR-ALL): A Children's Oncology Group (COG) Study. <i>Blood</i> , 2010, 116, 414-414.	0.6	0
294	ARID5B Genetic Polymorphisms Contribute to Racial Disparities In Childhood Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. <i>Blood</i> , 2010, 116, 8-8.	0.6	1
295	Administration of Erwinia Asparaginase (Erwinase®) Following Allergy to PEG-Asparaginase In Children and Young Adults with Acute Lymphoblastic Leukemia Treated on AALL07P2 Achieves Therapeutic Nadir Serum Asparaginase Activity: A Report From the Children's Oncology Group (COG). <i>Blood</i> , 2010, 116, 2134-2134.	0.6	3
296	Longer Time to the Start of Continuation Therapy Is Associated with Improved Survival In High Risk Pediatric Acute Lymphoblastic Leukemia (ALL): A Report From the Children's Oncology Group (COG). <i>Blood</i> , 2010, 116, 3223-3223.	0.6	0
297	Nelarabine May Be Safely Incorporated Into a Phase III Study for Newly Diagnosed T-Lineage Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. <i>Blood</i> , 2010, 116, 865-865.	0.6	2
298	Gene Expression Profiling Reveals Genes Predictive of Outcome In Infant Acute Lymphoblastic Leukemia (ALL) and Distinctive Age-Related Gene Expression Profiles (< 90 Days vs. > 90 Days): A Children's Oncology Group Study. <i>Blood</i> , 2010, 116, 412-412.	0.6	0
299	Young Adults With Acute Lymphoblastic Leukemia Have an Excellent Outcome With Chemotherapy Alone and Benefit From Intensive Postinduction Treatment: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2009, 27, 5189-5194.	0.8	128
300	JAK mutations in high-risk childhood acute lymphoblastic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 9414-9418.	3.3	516
301	Genome-wide Interrogation of Germline Genetic Variation Associated With Treatment Response in Childhood Acute Lymphoblastic Leukemia. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 393.	3.8	193
302	Dose-Intensified Compared With Standard Chemotherapy for Nonmetastatic Ewing Sarcoma Family of Tumors: A Children's Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 2536-2541.	0.8	294
303	Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 5175-5181.	0.8	643
304	Prevalence and clinical correlates of <i>JAK2</i> mutations in Down syndrome acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2009, 144, 930-932.	1.2	88
305	Beneficial and harmful effects of anthracyclines in the treatment of childhood acute lymphoblastic leukaemia: a systematic review and meta-analysis. <i>British Journal of Haematology</i> , 2009, 145, 376-388.	1.2	26
306	The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. <i>Leukemia</i> , 2009, 23, 1417-1425.	3.3	132

#	ARTICLE	IF	CITATIONS
307	Germline genomic variants associated with childhood acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2009, 41, 1001-1005.	9.4	459
308	Deletion of <i>IKZF1</i> and Prognosis in Acute Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2009, 360, 470-480.	13.9	1,260
309	Masked Hypodiploidy: Hypodiploid Acute Lymphoblastic Leukemia (ALL) in Children Mimicking Hyperdiploid ALL: A Report From the Children's Oncology Group (COG) AALL03B1 Study.. <i>Blood</i> , 2009, 114, 1580-1580.	0.6	7
310	Gene Expression Profiling in Down Syndrome Acute Lymphoblastic Leukemia Identifies Distinct Profiles Associated with CRLF2 Expression Status.. <i>Blood</i> , 2009, 114, 2389-2389.	0.6	1
311	Report On Excessive Induction Toxicity in Infants with ALL Enrolled On COG Protocol AALL0631: A Children's Oncology Group Study.. <i>Blood</i> , 2009, 114, 3091-3091.	0.6	4
312	Children with NCI Standard Risk Acute Lymphoblastic Leukemia (ALL) and TEL-AML1 or Favorable Chromosome Trisomies Are Almost Certain to Be Cured with Graduated Intensity Therapy: Results of the CCG - 1991 Study.. <i>Blood</i> , 2009, 114, 320-320.	0.6	1
313	Next Generation Transcriptomic Resequencing Identifies Novel Genetic Alterations in High-Risk (HR) Childhood Acute Lymphoblastic Leukemia (ALL): A Report From the Children's Oncology Group (COG) HR ALL TARGET Project.. <i>Blood</i> , 2009, 114, 704-704.	0.6	15
314	Mutations in the RAS Signaling, B-Cell Development, TP53/RB1, and JAK Signaling Pathways Are Common in High Risk B-Precursor Childhood Acute Lymphoblastic Leukemia (ALL): A Report From the Children's Oncology Group (COG) High-Risk (HR) ALL TARGET Project.. <i>Blood</i> , 2009, 114, 85-85.	0.6	10
315	Patients with Early T-Cell Precursor (ETP) Acute Lymphoblastic Leukemia (ALL) Have High Levels of Minimal Residual Disease (MRD) at the End of induction—A Children's Oncology Group (COG) Study.. <i>Blood</i> , 2009, 114, 9-9.	0.6	24
316	Specific MLL Partner Genes in Infant Acute Lymphoblastic Leukemia (ALL) Associated with Outcome Are Linked to Age and White Blood Cell Count (WBC) at Diagnosis: A Report On the Children's Oncology Group (COG) P9407 Trial.. <i>Blood</i> , 2009, 114, 907-907.	0.6	5
317	Secondary Chromosomal Abnormalities Appear to Be Less Prognostic for Children with Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with Intensified Imatinib and Chemotherapy: Results of the Children's Oncology Group (COG) Study AALL0031.. <i>Blood</i> , 2009, 114, 2606-2606.	0.6	2
318	Amplification of AML1 Does Not Impact Early Outcome of Children with Acute Lymphoblastic Leukemia (ALL) Treated with Risk-Directed Chemotherapy: A Report From the Children's Oncology Group (COG).. <i>Blood</i> , 2009, 114, 2598-2598.	0.6	6
319	Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study. <i>Leukemia</i> , 2008, 22, 2142-2150.	3.3	489
320	Outcomes after HLA-matched sibling transplantation or chemotherapy in children with acute lymphoblastic leukemia in a second remission after an isolated central nervous system relapse: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. <i>Leukemia</i> , 2008, 22, 281-286.	3.3	57
321	Reinduction Platform for Children With First Marrow Relapse of Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 3971-3978.	0.8	210
322	Prospective Analysis of <i>TEL</i> Gene Rearrangements in Childhood Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2008, 26, 2186-2191.	0.8	79
323	Expression of CD44, but not CD44v6, predicts relapse in children with B cell progenitor acute lymphoblastic leukemia lacking adverse or favorable genetics. <i>Leukemia and Lymphoma</i> , 2008, 49, 710-718.	0.6	12
324	Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology Group. <i>Blood</i> , 2008, 111, 2984-2990.	0.6	41

#	ARTICLE	IF	CITATIONS
325	A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group. <i>Blood</i> , 2008, 111, 4496-4499.	0.6	110
326	Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. <i>Blood</i> , 2008, 111, 5477-5485.	0.6	751
327	Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. <i>Blood</i> , 2008, 112, 4178-4183.	0.6	179
328	Prevalence and Clinical Correlates of JAK2 Mutations in Pediatric Down Syndrome Acute Lymphoblastic Leukemia.. <i>Blood</i> , 2008, 112, 1506-1506.	0.6	1
329	Increased Incidence of Osteonecrosis (ON) with a Dexamethasone (DEX) Induction for High Risk Acute Lymphoblastic Leukemia (HR-ALL): A Report from the Children's Oncology Group (COG).. <i>Blood</i> , 2008, 112, 898-898.	0.6	19
330	Escalating Dose Intravenous Methotrexate without Leucovorin Rescue during Interim Maintenance Is Superior to Oral Methotrexate for Children with Standard Risk Acute Lymphoblastic Leukemia (SR-ALL): Children's Oncology Group Study 1991. <i>Blood</i> , 2008, 112, 9-9.	0.6	12
331	Philadelphia Chromosome Negative (Ph-) Very High Risk (VHR) Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents: The Impact of Intensified Chemotherapy on Early Event Free Survival (EFS) in Children's Oncology Group (COG) Study AALL0031.. <i>Blood</i> , 2008, 112, 911-911.	0.6	1
332	Bone Marrow (BM) Minimal Residual Disease (MRD) at End of Induction and Interim Maintenance Is Highly Predictive of Outcome in Children with Standard Risk (SR) Acute Lymphoblastic Leukemia (ALL) Treated on the Children's Oncology Group Study 1991. <i>Blood</i> , 2008, 112, 701-701.	0.6	1
333	Genetically Defined Racial Differences Underlie Risk of Relapse in Childhood Acute Lymphoblastic Leukemia. <i>Blood</i> , 2008, 112, 14-14.	0.6	1
334	Acute Lymphoblastic Leukemia (ALL) with t(8;14)(q11.2;q32): B-Lineage Disease with High Proportion of Down Syndrome. A Children's Oncology Group (COG) Study.. <i>Blood</i> , 2008, 112, 1477-1477.	0.6	0
335	Evolution of Gene Expression Signatures in Relapsed Childhood Acute Lymphoblastic Leukemia Differs Based on Timing of Relapse.. <i>Blood</i> , 2008, 112, 3345-3345.	0.6	0
336	Pan-Anti-Apoptotic BCL-2 Family Inhibitor, Obatoclax, Activates Autophagic Cell Death Pathway and Has Potent Cytotoxicity in Infant and Pediatric MLL-Rearranged Leukemias. <i>Blood</i> , 2008, 112, 2647-2647.	0.6	1
337	Identification of Novel Cluster Groups in High-Risk Pediatric B-Precursor Acute Lymphoblastic Leukemia (HR-ALL) by Gene Expression Profiling: Correlation with Clinical and Outcome Variables. a Children's Oncology Group (COG) Study.. <i>Blood</i> , 2008, 112, 2256-2256.	0.6	0
338	Quantitative RT-PCR for Expression of a Small Subset of Genes Identifies Novel Prognostic Subgroups in High-Risk Pediatric Precursor B-Cell Acute Lymphoblastic Leukemia (HR-ALL): Clinical Applicability of Gene Expression Microarray Data from Children's Oncology Group Trials.. <i>Blood</i> , 2008, 112, 1514-1514.	0.6	0
339	Cell Death Regulatory Gene Expression Correlates with MLL Rearrangement Status and Prognostic Clinical Covariates in Acute Leukemia in Infants.. <i>Blood</i> , 2008, 112, 2255-2255.	0.6	0
340	Survival after Relapse in Higher Risk Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents Is Independent of Prior Treatment Intensity: A Report from the Children's Oncology Group (COG).. <i>Blood</i> , 2008, 112, 917-917.	0.6	0
341	Prognostic Role of the Reduced Folate Carrier, the Major Membrane Transporter for Methotrexate, in Childhood Acute Lymphoblastic Leukemia: A Report from the Children's Oncology Group. <i>Clinical Cancer Research</i> , 2007, 13, 451-457.	3.2	23
342	Vinblastine and Methotrexate for Desmoid Fibromatosis in Children: Results of a Pediatric Oncology Group Phase II Trial. <i>Journal of Clinical Oncology</i> , 2007, 25, 501-506.	0.8	176

#	ARTICLE	IF	CITATIONS
343	Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201. <i>Blood</i> , 2007, 110, 1105-1111.	0.6	52
344	Identification of genomic classifiers that distinguish induction failure in T-lineage acute lymphoblastic leukemia: a report from the Children's Oncology Group. <i>Blood</i> , 2007, 110, 1429-1438.	0.6	47
345	Intensified PEG-L-asparaginase and Antimetabolite-based Therapy for Treatment of Higher Risk Precursor-B Acute Lymphoblastic Leukemia. <i>Journal of Pediatric Hematology/Oncology</i> , 2007, 29, 369-375.	0.3	18
346	Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). <i>Blood</i> , 2007, 109, 926-935.	0.6	413
347	One- and two-stage designs for phase II window studies. <i>Statistics in Medicine</i> , 2007, 26, 2604-2614.	0.8	11
348	Prognostic significance of cytogenetically detected chromosome 21 anomalies in childhood acute lymphoblastic leukemia: a Pediatric Oncology Group study. <i>Cancer Genetics and Cytogenetics</i> , 2007, 175, 117-124.	1.0	12
349	Genome-Wide Profiling of High-Risk Pediatric Acute Lymphoblastic Leukemia (ALL): The ALL Pilot Project for the Therapeutically Applicable Research To Generate Effective Treatments (TARGET) Initiative.. <i>Blood</i> , 2007, 110, 229-229.	0.6	2
350	Improved Early Event Free Survival (EFS) in Children with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) with Intensive Imatinib in Combination with High Dose Chemotherapy: Children's Oncology Group (COG) Study AALL0031.. <i>Blood</i> , 2007, 110, 4-4.	0.6	25
351	Delayed Intensification (DI) Enhances Event-Free Survival (EFS) of Children with B-Precursor Acute Lymphoblastic Leukemia (ALL) Who Received Intensification Therapy with Six Courses of Intravenous Methotrexate (MTX): POG 9904/9905: A Children's Oncology Group Study (COG).. <i>Blood</i> , 2007, 110, 583-583.	0.6	2
352	Molecular Classifiers for Prediction of Minimal Residual Disease (MRD) and Event Free Survival (EFS) Improve Risk Assignment at Diagnosis in Pediatric High-Risk B Precursor Acute Lymphoblastic Leukemia (ALL): A Children's Oncology Group Study.. <i>Blood</i> , 2007, 110, 1422-1422.	0.6	0
353	Possible Advantage of Twice-Daily 6-Mercaptopurine Dosing in Children with Acute Lymphoblastic Leukemia (ALL).. <i>Blood</i> , 2007, 110, 851-851.	0.6	2
354	Outcomes for B-Precursor Patients in Legacy Children's Cancer Group (CCG) and Pediatric Oncology Group (POG) Studies in Childhood Acute Lymphoblastic Leukemia (ALL): A Children's Oncology Group (COG) Report.. <i>Blood</i> , 2007, 110, 847-847.	0.6	11
355	Expression Profiling Identifies Novel Genetic Subgroups with Distinct Clinical Features and Outcome in High-Risk Pediatric Precursor B Acute Lymphoblastic Leukemia (B-ALL). A Children's Oncology Group Study.. <i>Blood</i> , 2007, 110, 1430-1430.	0.6	0
356	Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. <i>Blood</i> , 2006, 107, 4961-4967.	0.6	154
357	Hematopoietic Stem Cell Transplantation After First Marrow Relapse of Non-T, Non-B Acute Lymphoblastic Leukemia. <i>Journal of Pediatric Hematology/Oncology</i> , 2006, 28, 210-215.	0.3	10
358	Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: A report of POG study 9296. <i>Pediatric Blood and Cancer</i> , 2006, 46, 179-186.	0.8	20
359	Does intravenous 6-mercaptopurine decrease salvage after relapse in childhood acute lymphoblastic leukemia?. <i>Pediatric Blood and Cancer</i> , 2006, 46, 660-661.	0.8	1
360	Resolution of ambiguous low-level positive quantitative polymerase chain reaction results in TEL-AML1 positive ALL using a post-PCR fluorescent oligoligation method. <i>British Journal of Haematology</i> , 2006, 135, 358-361.	1.2	1

#	ARTICLE	IF	CITATIONS
361	Perforin polymorphism A91V and susceptibility to B-precursor childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. <i>Leukemia</i> , 2006, 20, 1539-1541.	3.3	52
362	Isolated CNS Relapse of Acute Lymphoblastic Leukemia Treated With Intensive Systemic Chemotherapy and Delayed CNS Radiation: A Pediatric Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2006, 24, 3142-3149.	0.8	105
363	Intensive Therapy With Growth Factor Support for Patients With Ewing Tumor Metastatic at Diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457â€”A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2006, 24, 152-159.	0.8	132
364	Nelarabine Can Be Safely Incorporated into an Intensive, Multiagent Chemotherapy Regimen for the Treatment of T-Cell Acute Lymphocytic Leukemia (ALL) in Children: A Report of the Childrenâ€™s Oncology Group (COG) AALL00P2 Protocol for T-Cell Leukemia.. <i>Blood</i> , 2006, 108, 1864-1864.	0.6	3
365	Increased Infection-Related Mortality for Children with Down Syndrome (DS) in Contemporary Childrenâ€™s Oncology Group (COG) Acute Lymphoblastic Leukemia (ALL) Clinical Trials.. <i>Blood</i> , 2006, 108, 1865-1865.	0.6	18
366	Outcomes of Children with First Marrow Relapse: Results from Childrenâ€™s Oncology Group (COG) Study AALL01P2.. <i>Blood</i> , 2006, 108, 1871-1871.	0.6	3
367	Prognostic Significance of Minimal Residual Disease (MRD) in Childhood B-Precursor ALL and Its Relation to Other Risk Factors. A Childrenâ€™s Oncology Group (COG) Study.. <i>Blood</i> , 2006, 108, 219-219.	0.6	5
368	Outcomes after HLA-Matched Sibling Transplants or Chemotherapy in Children with Acute Lymphoblastic Leukemia in a Second Remission after an Isolated Central Nervous System Relapse.. <i>Blood</i> , 2006, 108, 49-49.	0.6	2
369	Prospective Analysis of TEL and MLL Gene Rearrangements in Childhood Acute Lymphoblastic Leukemia: A Childrenâ€™s Oncology Group Study.. <i>Blood</i> , 2006, 108, 218-218.	0.6	16
370	Testicular Relapse in Lesser, Standard, and High Risk Patients Treated with Frontline Therapy for Childhood ALL. <i>Pediatric Oncology Group Protocols 9201, 9405, 9605, and 9406.. Blood</i> , 2006, 108, 1863-1863.	0.6	0
371	Phase II Trial of Neoadjuvant Vincristine, Ifosfamide, and Doxorubicin With Granulocyte Colony-Stimulating Factor Support in Children and Adolescents With Advanced-Stage Nonrhabdomyosarcomatous Soft Tissue Sarcomas: A Pediatric Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 4031-4038.	0.8	99
372	Phase II Study of Nelarabine (compound 506U78) in Children and Young Adults With Refractory T-Cell Malignancies: A Report From the Childrenâ€™s Oncology Group. <i>Journal of Clinical Oncology</i> , 2005, 23, 3376-3382.	0.8	285
373	Prognostic Significance of Minimal Residual Disease (MRD) in Children with High Risk Acute Lymphoblastic Leukemia(ALL) A Childrenâ€™s Oncology Group Study.. <i>Blood</i> , 2005, 106, 85-85.	0.6	6
374	Thrombotic and Hemorrhagic Events for Patients on Pediatric Oncology Group (POG) Protocols 9201, 9605, 9406.. <i>Blood</i> , 2005, 106, 880-880.	0.6	1
375	A Report of the Event-Free Survival (EFS) and Neurotoxicity for Children with Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia (ALL) on Pediatric Oncology Group (POG) Protocol 9405.. <i>Blood</i> , 2005, 106, 882-882.	0.6	2
376	A Report of the Event Free Survival (EFS) for Children with Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia (ALL) Treated on Pediatric Oncology Group (POG) Protocol 9605.. <i>Blood</i> , 2005, 106, 875-875.	0.6	0
377	Perforin Polymorphism A91V and Susceptibility to Childhood Acute Lymphoblastic Leukemia (ALL).. <i>Blood</i> , 2005, 106, 1453-1453.	0.6	0
378	Minimal Residual Disease(MRD) in Childhood Acute Lymphoblastic Leukemia(ALL) in Relapse. A Childrenâ€™s Oncology Group (COG) Study.. <i>Blood</i> , 2004, 104, 324-324.	0.6	3

#	ARTICLE	IF	CITATIONS
379	Outcome of Children with T-Cell Acute Lymphoblastic Leukemia (T-ALL) and Standard Risk (SR) Features: Results of CCG-1952, CCG-1991 and POG 9404.. Blood, 2004, 104, 680-680.	0.6	3
380	Treatment of High Risk T-Cell Acute Lymphoblastic Leukemia (T-ALL): Comparison of Recent Experience of the Children's Cancer Group (CCG) and Pediatric Oncology Group (POG).. Blood, 2004, 104, 681-681.	0.6	6
381	Pharmacogenetics of Minimal Residual Disease Response in Children with Acute Lymphoblastic Leukemia (ALL).. Blood, 2004, 104, 451-451.	0.6	0
382	Presurgical Chemotherapy Compared With Immediate Surgery and Adjuvant Chemotherapy for Nonmetastatic Osteosarcoma: Pediatric Oncology Group Study POG-8651. Journal of Clinical Oncology, 2003, 21, 1574-1580.	0.8	363
383	Ewing Sarcoma/Primitive Neuroectodermal Tumor of the Chest Wall. Annals of Surgery, 2003, 238, 563-568.	2.1	97
384	Sequence alterations in the reduced folate carrier are observed in osteosarcoma tumor samples. Clinical Cancer Research, 2003, 9, 837-44.	3.2	46
385	Phase II/III Trial of Etoposide and High-Dose Ifosfamide in Newly Diagnosed Metastatic Osteosarcoma: A Pediatric Oncology Group Trial. Journal of Clinical Oncology, 2002, 20, 426-433.	0.8	129
386	Functional outcome after thoracoabdominal aortic aneurysm repair. Journal of Vascular Surgery, 2002, 35, 640-647.	0.6	98
387	Presurgical Window of Carboplatin and Surgery and Multidrug Chemotherapy for the Treatment of Newly Diagnosed Metastatic or Unresectable Osteosarcoma: Pediatric Oncology Group Trial. The American Journal of Pediatric Hematology/oncology, 2001, 23, 340-348.	1.3	65
388	Low-dose extrapolation using the power family of response functions. Computational Statistics and Data Analysis, 2001, 36, 311-317.	0.7	1
389	Venous Valve Station Changes in "Primary" and Postthrombotic Reflux: An Analysis of 149 Cases. Annals of Vascular Surgery, 2000, 14, 193-199.	0.4	31
390	Ambulatory Venous Hypertension: Component Analysis in 373 Limbs. Vascular Surgery, 1999, 33, 257-266.	0.3	18
391	Saphenectomy in the presence of chronic venous obstruction. Surgery, 1998, 123, 637-644.	1.0	38
392	Axial transformation of the profunda femoris vein. Journal of Vascular Surgery, 1998, 27, 651-659.	0.6	88
393	A Method for Determining Patient Oral Care Skills: The University of Mississippi Oral Hygiene Index. Journal of Periodontology, 1998, 69, 1176-1180.	1.7	15
394	A comparison of two different bronchial cuff designs and four different bronchial cuff inflation methods. Journal of Cardiothoracic and Vascular Anesthesia, 1997, 11, 599-603.	0.6	24
395	Psychopathologic Risk Factors for Intentional and Nonintentional Injury. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 42, 711-715.	1.1	57
396	PRODUCTION OF INTERLEUKIN-10 IN HUMAN FRACTURE SOFT-TISSUE HEMATOMAS. Shock, 1996, 6, 3-6.	1.0	51

#	ARTICLE	IF	CITATIONS
397	Glucose given after hypoxic ischemia does not affect brain injury in piglets.. Stroke, 1994, 25, 1443-1447.	1.0	51
398	Generalized logistic models for low-dose response data. Statistics in Medicine, 1993, 12, 881-892.	0.8	5
399	Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia. SSRN Electronic Journal, 0, , .	0.4	0